• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Immunotherapy

OncoSec announces positive results in metastatic melanoma case study

December 4, 2020 By Brian Buntz

Oncosec

The International Journal of Surgery Case Reports has published a case study on the use of the humanized antibody Keytruda (pembrolizumab) and tavokinogene telseplasmid (TAVO) from OncoSec (NSDQ:ONCS) for treating metastatic melanoma. The study involved a patient with stage IIB, pT3b melanoma who initially underwent tumor resection but experienced regional recurrence and later disease progression […]

Filed Under: Immunotherapy, Oncology, Surgical Tagged With: electroporation, Keytruda, melanoma, Oncosec, pembrolizumab, TAVO, tavokinogene telseplasmid

Inovio to scale up production of smart delivery device for potential COVID-19 vaccine

July 24, 2020 By Sean Whooley

Inovio Pharma

Inovio Pharmaceuticals (NSDQ:INO) announced that it received $71 million from the U.S. Defense Dept. to support its Cellectra 3PSP smart device. Funding from the DoD is set to support large-scale manufacturing for the Cellectra 3PSP and the procurement of Cellectra 2000 devices, which are used to deliver Inovio’s INO-4800 COVID-19 vaccine candidate directly into the skin. […]

Filed Under: Business/Financial News, Clinical Trials, Drug-Device Combinations, Featured, Funding Roundup, Immunotherapy Tagged With: coronavirus, COVID-19, Inovio Pharmaceuticals, U.S. Defense Dept.

MIT researchers think they’ve found a way to get more particles through a syringe

July 8, 2020 By Sean Whooley

Researchers at the Massachusetts Institute of Technology (MIT) are touting a computational model that could prevent microparticle clogging during injections. Microparticles, which are about the size of a grain of sand, can be difficult to inject if they get clogged in a typical syringe. The research team at MIT developed this new model that determines […]

Filed Under: Discovery, Drug-Device Combinations, Featured, Immunotherapy, Research & Development Tagged With: Massachusetts Institute of Technology

AbbVie gains U.S. nod for $63B Allergan takeover

May 6, 2020 By Nancy Crotti

Pharmaceutical giant  AbbVie (NYSE:ABBV) has won U.S. antitrust approval for its  purchase of Allergan (NYSE:AGN) for $63 billion in cash and stock. The purchase is seen as a hedge against the impending expiration of U.S. patents on AbbVie’s blockbuster drug, Humira. North Chicago-based AbbVie announced the deal in June 2019, but ran up against U.S. Federal Trade Commission […]

Filed Under: Business/Financial News, Featured, Immunotherapy, Pharmaceuticals, Wall Street Beat Tagged With: AbbVie, Allergan, AstraZeneca plc, Federal Trade Commission (FTC), Johnson & Johnson

OncoSec, Inovio testing COVID-19 vaccines

April 8, 2020 By Sean Whooley

OncoSec Medical (NSDQ:ONCS) and Inovio Pharmaceuticals (NSDQ:INO) announced that they are testing potential COVID-19 vaccines after the latter received investigational new drug clearance from the FDA. Inovio received an IND nod, while OncoSec’s is pending, but both companies are pursuing a first-in-human Phase 1 clinical trial for their vaccines, according to separate news releases. OncoSec is using […]

Filed Under: Business/Financial News, Clinical Trials, Discovery, Featured, Food & Drug Administration (FDA), Immunotherapy, Pharmaceuticals, Preclinical Trials, Regulatory/Compliance, Research & Development, Respiratory Tagged With: coronavirus, COVID-19, Inovio Pharmaceuticals, OncoSec Medical

TriSalus touts data for pressure-enabled drug-delivery tech

November 7, 2018 By Sarah Faulkner

TriSalus Life Sciences logo

TriSalus Life Sciences touted results today from a Phase Ib trial of its pressure-enabled drug-delivery tech for immunotherapy. The company reported that delivering a concentrated dose of CAR-T cells at the site of a solid tumor using its technology was safe and contributed to positive clinical results. In the early-stage trial, five patients with carcinoembryonic […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Immunotherapy, Pharmaceuticals Tagged With: Sorrento Therapeutics, trisaluslifesciences

OncoSec shares fall on preliminary data from skin cancer trial

November 6, 2018 By Sarah Faulkner

OncoSec

Shares in OncoSec Medical (NSDQ:ONCS) fell nearly -60% this morning after the company revealed preliminary data from its Phase IIb trial of intratumoral delivery of Tavo in people with unresectable, advanced melanoma. OncoSec’s lead product, Tavo, uses electroporation to deliver IL-12 directly into a patient’s tumor, triggering an immune response. As of Sept. 1, 21 people […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Immunotherapy, Oncology, Pharmaceuticals, Wall Street Beat Tagged With: Bristol-Myers Squibb Co., Merck, OncoSec Medical

Researchers develop nanodevice to deliver immunotherapy

October 25, 2018 By Sarah Faulkner

Houston Methodist - nanodevice

Researchers at Houston Methodist Research Institute have created a nanodevice that can be used to deliver immunotherapy to treat triple-negative breast cancer. The tiny device is designed to be inserted directly into a tumor, delivering a localized, sustained-release dose of therapy and eliminating the need for patients to undergo IV treatments. The scientists described their […]

Filed Under: Drug-Device Combinations, Featured, Immunotherapy, Oncology, Pharmaceuticals, Research & Development

Ichor touts use of electroporation drug-delivery system in cervical cancer trial

August 21, 2018 By Sarah Faulkner

Ichor Medical Systems

Ichor Medical Systems said today that its TriGrid electroporation drug-delivery system was tapped for a Phase Ib/II clinical trial to administer an investigational therapeutic HPV DNA vaccine, GX-188E, developed by Genexine Inc. The trial is designed to test the efficacy of a DNA vaccine combined with an anti-PD-1 therapy in patients with HPV-induced advanced non-resectable […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Immunotherapy, Oncology, Pharmaceuticals Tagged With: Ichor Medical Systems

BioEclipse looks to synergistic therapies to topple stubborn cancers

August 9, 2018 By Sarah Faulkner

BioEclipse Therapeutics logo

For the last 20 years, Pamela Contag has studied cancer. And in that time, the world’s understanding of cancer has changed dramatically. “I remember when people were saying ‘One gene, one protein,” which we now know is wrong,” she told Drug Delivery Business News. “And then we thought cancer was a disruption in proliferation and really […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Immunotherapy, Oncology, Pharmaceuticals Tagged With: bioeclipsetherapeutics

  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Interim pages omitted …
  • Go to page 6
  • Go to Next Page »

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by DrugDeliveryNow

Footer

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing
Medical Tubing + Extrusion

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery News
Advertise with us
About
Contact us
Privacy
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS